GLP-1 Drug Interactions: What to Know Before Adding or Changing Medications

GLP-1 receptor agonists have a clinically important but often misunderstood drug interaction profile. The good news: they do not interact via the CYP450 enzyme system that drives most major drug-drug interactions. The more nuanced issue: delayed gastric emptying affects oral drug absorption.

This article awaits medical-reviewer signoff.

The interaction mechanism: delayed gastric emptying

GLP-1 agonism slows gastric emptying — the rate at which the stomach passes its contents into the small intestine. This is the mechanism behind satiety and weight loss. It is also the mechanism behind GLP-1's drug interaction profile.

Most oral medications are absorbed primarily from the small intestine. Delayed gastric emptying means:

• The medication spends more time in the stomach before reaching the small intestine
• Peak plasma concentration (Cmax) may be lower or delayed
• Time to maximum absorption (Tmax) is extended
• In drugs where absorption rate drives efficacy (rapidly acting drugs), this can reduce clinical effect

What it does not affect: Medications given parenterally (injected), transdermally (patch), sublingually, or via inhalation are not affected by gastric emptying rate.

Clinically significant interactions

Cyclosporine and tacrolimus (transplant immunosuppressants)

These drugs require precise blood-level management — too low risks rejection; too high risks toxicity. Absorption variability from delayed gastric emptying can destabilise levels that were previously controlled.

Clinical management: Patients on cyclosporine or tacrolimus who start a GLP-1 drug should have immunosuppressant levels monitored more frequently during dose escalation, with prescriber guidance on timing adjustments. Consider giving cyclosporine at least 2 hours before the main GLP-1 pharmacodynamic effect period.

The Wegovy prescribing information specifically flags cyclosporine as a medication requiring monitoring.

Digoxin

Digoxin has a narrow therapeutic window and is affected by absorption variability. The GLP-1 label data shows modest effects on digoxin pharmacokinetics.

Clinical management: Patients on digoxin who start a GLP-1 drug may require digoxin level monitoring, particularly during dose escalation.

Warfarin

Warfarin anticoagulation (INR) is affected by multiple factors including dietary changes (vitamin K intake), which GLP-1 therapy affects as food intake patterns change. The label recommends INR monitoring when starting GLP-1 therapy in anticoagulated patients.

Note: Direct oral anticoagulants (DOACs — apixaban, rivaroxaban, edoxaban, dabigatran) have different pharmacokinetic profiles. Dabigatran absorption can be affected by gastric emptying and pH; the others are less affected. Monitor for unexpected anticoagulation changes with any GLP-1 initiation.

Oral contraceptives

Pharmacokinetic studies with semaglutide 1 mg showed modestly reduced Cmax and delayed Tmax for a combined oral contraceptive. Ethinyl oestradiol and levonorgestrel AUC (total drug exposure) was largely maintained.

Label guidance: The Ozempic prescribing information states: "If the concomitant oral medication is dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, the patient should be advised to take that drug at least 1 hour before or 4 hours after semaglutide injection."

In practice: some prescribers recommend back-up contraception (condoms) during the dose escalation phase of semaglutide or tirzepatide therapy as a precautionary measure. Non-oral contraception (patch, ring, IUD, injection) is not affected.

Antibiotics (narrow-window oral antibiotics)

For antibiotics where achieving adequate Cmax rapidly matters (e.g., certain antibiotics for acute bacterial infections), delayed absorption from GLP-1 gastric slowing is a theoretical concern. In most practical scenarios, the clinical effect is minimal. For courses where rapid achievement of therapeutic concentrations is critical, prescriber awareness is appropriate.

Interactions not primarily via gastric emptying

Insulin and sulfonylureas

Adding a GLP-1 drug to insulin or sulfonylurea therapy in T2D creates hypoglycaemia risk — not because of pharmacokinetic interaction, but because both classes lower blood glucose via different mechanisms. When added together, the combined effect can produce blood glucose below the safe threshold.

This is the most common clinically significant interaction for T2D patients. It is covered in detail in the GLP-1 and hypoglycaemia guide.

Lithium

Lithium absorption from the small intestine is not dramatically affected by gastric emptying rate in most patients. However, dietary changes and hydration changes from GLP-1 therapy can affect lithium levels (lithium is handled by the kidney similar to sodium — dehydration concentrates it). Patients on lithium who start GLP-1 therapy should monitor lithium levels, particularly during periods of GI side effects with reduced fluid intake.

General recommendation

Disclose all medications to your prescriber when starting a GLP-1 drug. This includes:

• All prescription medications
• Over-the-counter medications taken regularly
• Supplements and vitamins
• Oral contraceptives
• Any anticoagulants, immunosuppressants, or narrow-window drugs

The prescriber can identify clinically significant interactions and adjust monitoring or timing accordingly.

Editorial note: This article awaits medical-reviewer signoff. Drug interaction management requires the prescriber to review the full medication list. Do not adjust medications without consulting your prescriber or pharmacist.